Helus Pharma reported unaudited financial results for the third quarter ended December 31, 2025, highlighting continued progress across its clinical programs while completing a leadership transition and corporate rebranding. The clinical-stage pharmaceutical company developing novel serotonergic agonists ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized the company's strengthened balance sheet, expanding intellectual property portfolio, and upcoming clinical data milestones in 2026.
The company's HLP003 Phase 3 program for major depressive disorder has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, representing a significant regulatory milestone. HLP003 is being developed as an adjunctive treatment for major depressive disorder, while HLP004 is in Phase 2 development for generalized anxiety disorder. Both programs involve proprietary novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity, addressing unmet needs in mental health treatment.
Helus Pharma aims to improve the treatment landscape through the introduction of novel serotonergic agonists that provide durable improvements in mental health. The company's extensive research portfolio includes multiple investigational compounds beyond its lead candidates. The financial results and clinical progress come during a period of corporate transformation, with the company operating under its new commercial name while maintaining its commitment to developing treatments for depression, anxiety, and other mental health conditions.
The company's financial position, with substantial cash reserves, supports continued advancement of its clinical programs through key data readouts expected in 2026. For more information about the company's financial results, visit https://ibn.fm/VigPf. The company operates in multiple countries including Canada, the United States, the United Kingdom, and Ireland, with additional information available at https://www.helus.com. The latest news and updates relating to the company are available at https://ibn.fm/HELP.
